CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

CVS and Novo Nordisk have struck a deal that will see the drugstore chain offering the Wegovy weight-loss drug to customers ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...